BC
IART icon

Bridgefront Capital’s Integra LifeSciences IART Stock Holding History

Bridgefront Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,779
Closed -$158K – 633
2026
Q1 		$158K Buy
+16,779
New +$184K 0.04% 484
2024
Q4 		– Sell
-11,645
Closed -$212K – 677
2024
Q3 		$212K Buy
+11,645
New +$270K 0.08% 441
2023
Q3 		– Sell
-16,348
Closed -$672K – 490
2023
Q2 		$672K Buy
16,348
+12,254
+299% +$590K 0.36% 66
2023
Q1 		$235K Buy
+4,094
New +$231K 0.14% 286
2022
Q2 		– Sell
-4,116
Closed -$264K – 365
2022
Q1 		$264K Sell
4,116
-2,491
-38% -$164K 0.32% 138
2021
Q4 		$443K Buy
+6,607
New +$447K 0.43% 64
2021
Q3 		– Sell
-6,684
Closed -$456K – 501
2021
Q2 		$456K Buy
+6,684
New +$473K 0.17% 208

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Bridgefront Capital's IART Position: Q2 2026 in Review

Bridgefront Capital sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 16,779 shares — an estimated $158K sold.

Bridgefront Capital first reported a position in IART in Q2 2021 and held it in 7 quarters. The position peaked at $672K in Q2 2023. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Bridgefront Capital reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 16,779 Integra LifeSciences shares in Q2 2026, an estimated $158K.
  • Bridgefront Capital first reported a position in Integra LifeSciences in Q2 2021 and held it in 7 quarters.
  • Bridgefront Capital's Integra LifeSciences position peaked at $672K in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.